| Name | Title | Contact Details |
|---|
Integris Southwest Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Integris Southwest Medical Center is based in Oklahoma City, OK. You can find more information on Integris Southwest Medical Center at www.integrishealth.com
For 30 years, Accra has improved the lives of Minnesotans by providing individualized homecare services to people with disabilities and older adults, most of whom are Medicaid enrollees. Accra is a nonprofit organization that operates in all counties throughout Minnesota and has offices across the state, providing a familiar presence in local communities. Accra`s self-directed services support the independence of children, adolescents, and adults with disabilities, chronic diseases, behavioral diagnoses, and mental illnesses, who need assistance with personal care in the home and activities of daily living.
Trimedyne is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TigerConnect is healthcare`s most widely adopted communication platform – uniquely modernizing care collaboration among doctors, nurses, patients, and care teams. TigerConnect is the only solution that combines a consumer-like user experience for text, video, and voice communication with the serious security, privacy, and clinical workflow requirements that today`s healthcare organizations demand. TigerConnect accelerates productivity, reduces costs, and improves patient outcomes. Trusted by more than 5,000 healthcare organizations, TigerConnect maintains 99.99% verifiable uptime and processes more than 10 million messages each day.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.